Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland

BACKGROUND: Hyperphosphataemia is common and harmful in patients receiving dialysis. Treatment options include noncalcium-based phosphate binders such as sevelamer carbonate (SC) and sucroferric oxyhydroxide (PA21). OBJECTIVE: The aim of this study was to determine the health economic impact of PA21...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacoeconomics
Main Authors: Gutzwiller, Florian S., Pfeil, Alena M., Ademi, Zanfina, Blank, Patricia R., Braunhofer, Peter G., Szucs, Thomas D., Schwenkglenks, Matthias
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2015
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4661221/
https://ncbi.nlm.nih.gov/pubmed/26334991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-015-0320-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados